Back to Search
Start Over
Clinical systemic lupeol administration for canine oral malignant melanoma.
- Source :
-
Molecular & Clinical Oncology . 2015, Vol. 3 Issue 1, p89-92. 4p. - Publication Year :
- 2015
-
Abstract
- Canine oral malignant melanoma (COMM) is the most aggressive malignant tumor in dogs. Lupeol is a triterpene extracted from various fruits and vegetables that reportedly inhibits melanoma cell proliferation in vitro and in vivo. In this study, the efficacy of subcutaneous lupeol for spontaneous COMM was evaluated. A total of 11 dogs (3, 5 and 3 dogs diagnosed with clinical stage I, II and III melanoma, respectively) were evaluated. Subcutaneous lupeol (10 mg/kg) was administered postoperatively at various time points to treat these 11 COMM cases. Of the 11 subjects, 7 exhibited no local recurrence 180 days postoperatively and no severe adverse effects were observed in any of the cases. Furthermore, no distant metastasis was observed during the experimental period. Therefore, systemic lupeol may prevent local tumor progression and distant metastasis and may be a novel adjuvant treatment for the treatment of COMM. [ABSTRACT FROM AUTHOR]
- Subjects :
- *TUMORS
*MELANOMA
*ADJUVANT treatment of cancer
*TRITERPENES
*METASTASIS
Subjects
Details
- Language :
- English
- ISSN :
- 20499450
- Volume :
- 3
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Molecular & Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 100073945
- Full Text :
- https://doi.org/10.3892/mco.2014.450